Cargando…

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker

Detalles Bibliográficos
Autor principal:	El Osta, Badi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326771/ https://www.ncbi.nlm.nih.gov/pubmed/37425416 http://dx.doi.org/10.21037/tlcr-23-174

Ejemplares similares

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead
por: Li, Hui-yu, et al.
Publicado: (2021)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019)

Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”
por: Nagasaka, Misako, et al.
Publicado: (2023)

Cracking KRAS(G12C) across all solid tumors: the new kid on the block for tissue-agnostic precision medicine
por: Bhamidipati, D., et al.
Publicado: (2023)

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Therapeutic targeting of “undruggable” MYC
por: Llombart, Victor, et al.
Publicado: (2021)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

Drugging the “undruggable” DNA-binding domain of STAT3
por: Zhang, Jian-Ting, et al.
Publicado: (2016)

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
por: Salem, Mohamed E., et al.
Publicado: (2022)

Targeting STATs for cancer therapy: “Undruggable” no more
por: Frank, David A.
Publicado: (2012)

Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021)

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2022)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
por: Poso, Antti
Publicado: (2021)

Targeting the “undruggable” RAS - new strategies - new hope?
por: Mörchen, Britta, et al.
Publicado: (2019)

Targeting KRAS(G12C)-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
por: Ji, Jingran, et al.
Publicado: (2022)

The current landscape of using direct inhibitors to target KRAS(G12C)-mutated NSCLC
por: Batrash, Firas, et al.
Publicado: (2023)

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS
por: Pang, Jia Meng, et al.
Publicado: (2023)

Agnostic Tendency in Doctors
Publicado: (1885)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
por: Pirlog, Radu, et al.
Publicado: (2022)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
por: Lu, Bin, et al.
Publicado: (2021)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
por: Bond, Michael J., et al.
Publicado: (2020)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets
por: Moon, Seonghyeon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fd9rp211hskn76bnl0t820pg7p